Related Experiment Videos
Anti-tumor effect of dithiole compounds.
E Yoshida1, T Fukami, K Takamiya
1Exploratory Research Laboratories, Banyu Pharmaceutical Co., Ltd, Tokyo, Japan.
Anti-Cancer Drug Design
|August 1, 1988
Summary
New dithiole compounds show potent anti-tumor effects. The compound EX-015, with n-decyl chains, significantly increased survival in mice with leukemia by inhibiting RNA and protein synthesis.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Oncology
Background:
- Dithiole compounds represent a class of molecules with potential therapeutic applications.
- Investigating novel anti-cancer agents is crucial for improving patient outcomes.
Purpose of the Study:
- To synthesize and evaluate the anti-tumor activity of novel N-(1,3-dithiole-2-ylidene)-N,N-dialkyl-ammonium salts.
- To determine the structure-activity relationship of these compounds, focusing on alkyl chain length.
- To assess the efficacy of the most promising compound in a preclinical leukemia model.
Main Methods:
- Synthesis of a series of N-(1,3-dithiole-2-ylidene)-N,N-dialkyl-ammonium salts.
- In vitro cytotoxicity assays against cultured tumor cells.
- In vivo studies using mice bearing L1210 leukemic cells.
- Assessment of RNA, DNA, and protein synthesis inhibition.
Main Results:
- Most synthesized compounds displayed potent in vitro cytotoxic activity (IC50 < 1 µg/mL).
- The anti-tumor activity correlated with the length of the alkyl chains.
- EX-015, featuring n-decyl chains, demonstrated the most significant in vivo efficacy.
- EX-015 prolonged the survival of L1210-bearing mice by 69% at 0.8 mg/kg/day for 5 days.
- EX-015 inhibited RNA and protein synthesis in L1210 cells, with less impact on DNA synthesis.
Conclusions:
- Novel dithiole derivatives exhibit significant anti-cancer potential.
- EX-015 is a highly effective anti-leukemic agent in preclinical models.
- The mechanism of action involves the inhibition of RNA and protein synthesis.